Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.4 USD | -1.20% | -0.71% | -21.95% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 18.9B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.42 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.15 x |
P/E ratio 2024 * |
-42.3
x | P/E ratio 2025 * |
-80.2
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -1.20% | ||
1 week | -0.71% | ||
Current month | +3.79% | ||
1 month | +2.81% | ||
3 months | +1.63% | ||
6 months | -8.75% | ||
Current year | -21.95% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | +0.15% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 149.4 | -1.20% | 481,247 |
24-05-16 | 151.2 | +2.59% | 934,860 |
24-05-15 | 147.4 | -0.33% | 536,143 |
24-05-14 | 147.9 | -1.33% | 604,966 |
24-05-13 | 149.9 | -0.39% | 512,792 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.95% | 18.9B | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- ALNY Stock